Latigo Biotherapeutics Reports Q2 Financial Results
Latigo Biotherapeutics (NASDAQ:LTGO) reported its second-quarter financial results with a cash and cash equivalents balance of $55.0 million as of June 30, 2026. The company's research and development expenses for the quarter were $21.2 million, slightly lower than the previous period’s $22.9 million. The reduction in R&D spending indicates a potential shift or optimization in resource allocation during Q2 compared to earlier periods. With over $50 million in cash on hand, Latigo appears well-positioned financially as it continues its development efforts.
Topics: cash_position r_and_d_expenses